Bayes 2023

DAY 1 – 25th October

TIME

SPEAKER

AFFILIATION

08:30 - 09:00

Registration

09:00 - 12:30

Thomas Jaki, Pavel Mozgunov

University of Cambridge

SHORT COURSE:
Basket trials – a powerful tool for precision medicine trials

12:30 - 13:30

Lunch

13:30 - 13:45

Welcome and Opening

13:45 - 14:15

Kit Roes

Radboud University Nijmegen Medical Centre

Exploring regulatory perspectives on Bayesian statistics in assessment and decision making

14:15 - 14:35

Bradley P. Carlin

PharmaLex

Bayesian Adaptive Phase I-II designs for Evaluating Safety and Efficacy in Dual-Agent Oncological Drug Development

14:35 - 14:55

Jan Priel

Cytel

A confirmatory adaptive Phase II/III design with Bayesian decision rules for dose selection and sample size re-estimation – a case study

14:55 - 15:15

Leonhard Held

University of Zurich

A Bayesian Perspective on the Two-Trial Rule

15:15 - 15:40

Coffee break

15:40 - 16:10

François Beckers

Sanofi-Pasteur

Application of Bayesian approaches in drug development: starting a virtuous cycle

16:10 - 16:30

Lauren J. Frazee

PharmaLex

Issues in Regulatory Acceptability of Bayesian Historical Data Borrowing Methods

16:30 - 16:50

Peter van de Ven

University Medical Center Utrecht

A new Bayesian adaptive decision-theoretic design for multi-arm multi-stage clinical trials illustrated by an application in exercise oncology

The BAYES Organising Committee is delighted to invite all registered attendees to the social dinner at Stadskasteel Oudaen

DAY 2 – 26th October

TIME

SPEAKER

AFFILIATION

PRESENTATION

08:30 - 09:00

Joost van Rosmalen

Erasmus MC

Augmenting treatment arms with external data through propensity-score weighted power-priors: an application in expanded access

09:00 - 09:20

Annette Kopp-Schneider

German Cancer Research Center

Operating characteristics of clinical trials with borrowing from external data: one-arm and hybrid control arm trials

09:20 - 09:40

Emma K Mackay

Cytel

A Novel Information Borrowing Approach for Evaluating Response in Pediatric Basket Trials with Limited Sample Sizes

09:40 - 10:00

Samuel Pawel

University of Zurich

Power Priors for Replication Studies

10:00 - 10:25 MY TALK IN 3 MINUTES

Tanzy Love

University of Rochester

Clustering historical controls for a continuous outcome in a Bayesian Phase II vulvodynia trial design

Giles Partington

Phastar

Bayesian Elicitation for rare diseases trials

Wilmar Igl

Icon

Hype, Not Hope: Using Bayesian Methods in Drug Development

Forrest Williamson

Eli Lilly & Company

A Bioethical Defense of Bayesian Methods in Drug Development

Tanja Krone

Netherlands Organization for Applied Scientific research (TNO)

Bayesian Network Models to combine and update models using incomplete data

10:25 - 10:50

Coffee break

10:50 - 11:20

Ethan Alt

University of North Carolina on Chapel Hill, USA

LEAP: The latent exchangeability prior for borrowing information from historical data

11:20 - 11:40

Silvia Calderazzo

German Cancer Research Center

Robust incorporation of external information in hypothesis testing

11:40 - 12:00

Anduena Rexhepi

Boehringer Ingelheim

Systematic Value Exploration of Propensity Score and Borrowing Approaches

12:00 - 12:20

František Bartoš

University of Amsterdam

Empirical prior distributions for Bayesian meta-analyses of binary and time to event outcomes

12:20 - 13:20

Lunch

13:20 - 13:50

Veera Baladandayuthapani

University of Michigan

Bayesian Models for Multi-omic Multi-system Integration

13:50 - 14:10

Hakem Ben Addi

GSK Vaccines

Longitudinal Analysis of In Vivo mRNA Expression Data Using Bayesian P-Splines

14:10 - 14:30

Yimer Wasihun Kifle

Janssen Pharmaceutical

Formulating two classes of power priors to leverage historical accelerated stability data

14:30 - 14:50

Francisca Galindo Garre

Janssen Pharmaceutical

Advantages of using the Bayesian Framework for Modelling the relationship between Volume, Freezing Rate, Supercooling and Aggregation in Vaccines

14:50 - 15:15
MY TALK IN 3 MINUTES

Tobias Eilert

Boehringer Ingelheim

A Modern Approach to Stability Studies via Bayesian Linear Mixed Models Incorporating Auxiliary Effects

Juho Timonen

Aalto University & Generable Inc.

Longitudinal Gaussian Process Modeling in Biostatistics

Lira Pi

PharmaLex

Bayesian inference model with nested effects to perform differential gene expression analysis from multi-level spatial transcriptomics data with multiple conditions

Clément Laloux

PharmaLex

Penalized Bayesian Methods for Product Ranking Using Both Positive and Negative References

15:15 - 15:40

Coffee break

15:40 - 16:10

Lisa Hampson

Novartis

Quantitative Decision Making for drug development: the role of Bayesian methods in evaluating and communicating risk

16:10 - 16:30

James Salsbury

University of Sheffield

Assurance methods for designing a survival trial with delayed treatment effects

16:30 - 16:50

Anaïs Andrillon

Saryga

Surv-CRM-12: A Bayesian phase I/II survival CRM for right-censored toxicity endpoints with competing disease progression

16:50 - 17:10

Rajat Mukherjee

Mukherjee-Consultants

Interim Decisions with Time-to-Event Endpoints under Non-proportionality of Hazards

17:10 - 17:30

Sandrine Micallef

Debiopharm International SA

U-DESPA: a Utility-based Bayesian approach for dosage optimization relying on Dose-Exposure- Safety/Pharmacodynamics/anti-tumor activity relationship modeling for oncology clinical trials

DAY 3 – 27th October

TIME

SPEAKER

AFFILIATION

PRESENTATION

08:30 - 09:00

Sarah Zohar

INSERM

Coping with Information Loss and the Use of Auxiliary Sources of Data: A Report from the NISS Ingram Olkin Forum Series on Unplanned Clinical Trial Disruptions

09:00 - 09:20

Greg Papageorgiou

GSK Vaccines

Joint modeling for the prediction of exacerbation events in patients with COPD

09:20 - 09:40

Francois Mercier

Roche Innovation Center Basel

Democratizing Bayesian joint models in clinical drug development: From premise to daily practice in oncology

09:40 - 10:00

Georgios Kazantzidis

Roche

Non-linear Bayesian joint models to estimate direct and indirect treatment effects in oncology clinical trials

10:00 - 10:20

James Willard

McGill University

Bayesian Optimization for Dual Agent Dose-Finding Trials

10:20 - 10:45

Coffee break

10:45 - 11:15

J. Kyle Wathen

Cytel

In a Sea of Design Options – Using Visualization to Navigate A Variety of Options for a Platform Trial

11:15 - 11:35

Dario Zocholl

Charité Universitaetsmedizin Berlin

Estimating the similarity between adult and pediatric dose-toxicity curves to inform pediatric dose-finding.

11:35 - 11:55

Christian Stock

Boehringer Ingelheim

Partial extrapolation in pediatric drug development using robust meta-analytic predictive priors, tipping point analysis and expert elicitation

11:55 - 12:15

Lan Tran

PharmaLex

Using R-INLA in Bayesian Adaptive Designs

12:15 - 12:35

Eric-Jan Wagenmakers

University of Amsterdam

Interim Design Analysis Using Bayes Factor Forecasts